



Market Announcement

16 July 2020

Genetic Technologies Limited (ASX: GTG) – Trading Halt

Description

The securities of Genetic Technologies Limited ('GTG') will be placed in trading halt at the request of GTG, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 20 July 2020 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)

16 July 2020

Melissa Kostopoulos
ASX Compliance Pty Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

Dear Melissa

Trading Halt Request

Pursuant to ASX Listing Rule 17.1, Genetic Technologies Limited ('Company') requests a trading halt in anticipation of an announcement regarding a pending ASX query in relation to price movement.

The trading halt will remain in place until the earlier of the commencement of normal trading on Monday 20 July 2020, or until the release of the announcement in respect of the above matter.

The Company is not aware of any reason why the trading halt should not be granted.

Yours sincerely

Justyn Stedwell
Company Secretary
On behalf of the Board of Directors
Genetic Technologies Limited

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company's lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class.

Genetic Technologies has capacity for COVID-19 testing and is developing a pipeline of risk assessment products.

For more information, please visit www.gtglabs.com.